세계의 생물제제 안전성 시험 시장 : 제품/서비스별, 시험 유형별, 용도별 - 예측(-2029년)
Biologics Safety Testing Market by Product & Service (Consumables, Instrument, Services), Test Type (Mycoplasma, Sterility, Endotoxin, Bioburden, Virus Safety), Application (Vaccines, mAbs, Cell & Gene Therapy, Blood Products) - Global Forecast to 2029
상품코드:1479742
리서치사:MarketsandMarkets
발행일:2024년 05월
페이지 정보:영문 387 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계 생물제제 안전성 시험 시장 규모는 2024년 약 42억 달러에서 2029년까지 72억 달러에 달할 것으로 예상되며, 2024-2029년간 연평균 11.1% 성장할 것으로 예상됩니다.
시장의 성장은 신규 생물제제 개발 및 제조에 대한 관심이 높아졌기 때문인 것으로 보입니다. 만성질환 증가로 인해 세포치료제, 유전자치료제 등 첨단 치료법에 대한 수요가 증가하면서 생물제제 안전성 시험의 성장을 견인하고 있습니다. 이러한 추세는 향후 몇 년간 생물제제 안전성 시험 시장의 성장을 가속할 것으로 예상됩니다.
조사 범위
조사 대상년도
2022년-2029년
기준년도
2023년
예측 기간
2024년-2029년
단위
10억 달러
부문
제품 및 서비스, 테스트 유형, 용도, 최종 사용자
대상 지역
북미, 유럽, 아시아태평양, 라틴아메리카, 중동/아프리카
"용도별로는 단클론항체 개발 및 제조 부문이 2023년 가장 큰 비중을 차지할 것으로 예상됩니다."
2023년 단클론항체 개발 및 제조 부문은 용도별로 세계 시장에서 가장 큰 점유율을 차지할 것으로 예상됩니다. 새로운 생물학적 치료법 개발에 대한 투자 및 자금 조달과 만성 질환 치료를 위한 생물학적 요법에 대한 수요 증가가 생물제제 안전성 시험 시장의 성장을 가속하고 있습니다.
"미국은 2024-2029년에도 시장을 계속 독점할 것입니다."
미국이 2023년 북미 시장을 장악했습니다. 미국은 세계 최대 바이오의약품 시장이자 바이오의약품 연구/투자의 선두주자입니다. 또한 미국은 생명과학 부문의 연구개발을 촉진하는 강력한 의료 인프라를 보유하고 있습니다. 또한, 미국에는 다수의 바이오제약 기업이 존재하며, 바이오제약 기업 증가와 생명공학 부문의 연구 활동이 활발해지면서 미국 시장의 성장을 견인하고 있습니다. 또한, 바이오시밀러의 승인 증가는 생물제제 안전성 시험 시장의 성장을 가속하고 있습니다.
본 보고서는 세계 생물제제 안전성 시험 시장에 대해 조사 분석했으며, 주요 촉진요인과 억제요인, 경쟁 구도, 향후 동향 등의 정보를 전해드립니다.
목차
제1장 서론
제2장 조사 방법
제3장 주요 요약
제4장 프리미엄 인사이트
생물제제 안전성 시험 시장 개요
북미의 생물제제 안전성 시험 시장 : 제품 및 서비스별, 국가별(2023년)
생물제제 안전성 시험 시장 점유율 : 용도별(2023년)
생물제제 안전성 시험 시장 점유율 : 최종사용자별(2023년)
생물제제 안전성 시험 시장 : 지역 목표 성장 기회
제5장 시장 개요
서론
시장 역학
성장 촉진요인
성장 억제요인
기회
과제
기술 분석
주요 기술
보완 기술
인접 기술
공급망 분석
밸류체인 분석
가격 분석
생태계 분석
생물제제 안전성 시험 시장의 원재료 벤더
생물제제 안전성 시험 시장의 제품 벤더
생물제제 안전성 시험 시장의 서비스 제공업체
생물제제 안전성 시험 시장의 최종사용자
생물제제 안전성 시험 시장을 총괄하는 규제기관
고객의 비즈니스에 영향을 미치는 동향/혼란
특허 분석
주요 컨퍼런스 및 이벤트
규제 상황
서론
규제기관/정부기관/기타 조직
규제 시나리오
Porter의 Five Forces 분석
주요 이해관계자와 구입 기준
투자/자금조달 시나리오
제6장 생물제제 안전성 시험 시장 : 제품 및 서비스별
서론
서비스
마이코플라스마 시험 서비스
무균 시험 서비스
엔도톡신 시험 서비스
바이러스 안전성 시험 서비스
바이오바덴 시험 서비스
기타 생물제제 안전성 시험 서비스
소모품
기기
제7장 생물제제 안전성 시험 제품 시장 : 시험 유형별
서론
잔류 숙주세포 유래 단백질 및 DNA 탐지 시험
마이코플라스마 시험
무균 시험
엔드트키신 시험
바이러스 안전성 시험
바이오바덴 시험
기타 생물제제 안전성 시험
제8장 생물제제 안전성 시험 시장 : 용도별
서론
단클론항체 개발 및 제조
백신 개발 및 제조
세포 및 유전자 치료 제품 개발 및 제조
혈액 및 혈액 제품 개발 및 제조
기타 용도
제9장 생물제제 안전성 시험 시장 : 최종사용자별
서론
제약 기업 및 바이오테크놀러지 기업
CRO 및 CDMO
학술기관 및 연구기관
제10장 생물제제 안전성 시험 시장 : 지역별
서론
북미
북미에 대한 불황의 영향
미국
캐나다
유럽
유럽에 대한 불황의 영향
독일
영국
프랑스
이탈리아
스페인
기타 유럽
아시아태평양
아시아태평양에 대한 불황의 영향
중국
일본
인도
한국
호주
기타 아시아태평양
라틴아메리카
라틴아메리카에 대한 불황의 영향
브라질
멕시코
기타 라틴아메리카
중동
중동에 대한 불황의 영향
GCC 국가
기타 중동
아프리카
제11장 경쟁 구도
서론
주요 기업의 전략/유력 기업
매출 분석
시장 점유율 분석
브랜드/제품 비교
기업 평가 매트릭스 : 주요 기업(2023년)
기업 평가 매트릭스 : 스타트업/중소기업(2023년)
평가와 재무 지표
경쟁 시나리오
제12장 기업 개요
서론
주요 기업
THERMO FISHER SCIENTIFIC INC.
CHARLES RIVER LABORATORIES
LABORATORY CORPORATION OF AMERICA HOLDINGS
F. HOFFMANN-LA ROCHE LTD.
MERCK KGAA
SARTORIUS AG
LONZA
FUJIFILM CORPORATION
BIOMERIEUX
MARAVAI LIFESCIENCES
WUXI APPTEC
SGS SOCIETE GENERALE DE SURVEILLANCE SA.
SOTERA HEALTH
SAMSUNG BIOLOGICS
GENSCRIPT
AGILENT TECHNOLOGIES, INC.
SYNGENE INTERNATIONAL LIMITED
EUROFINS SCIENTIFIC
BIO-RAD LABORATORIES, INC.
QIAGEN
기타 기업
PROMEGA CORPORATION
CATALENT, INC.
ASSOCIATES OF CAPE COD, INC.
CLEAN BIOLOGICS
PATHOQUEST
PACIFIC BIOLABS
ARL BIO PHARMA, INC.
FRONTAGE LABS
CREATIVE BIOGENE
ADVAXIA BIOLOGICS
제13장 디스커션 가이드
LSH
영문 목차
영문목차
The biologics safety testing market is projected to reach USD 7.2 billion by 2029 from an estimated USD 4.2 billion in 2024, at a CAGR of 11.1% from 2024 to 2029. The growth of this market can be attributed to the increasing focus on the development and manufacturing of novel biologics. The rising demand for advanced therapies such as cell and gene therapies due to the growing rate of chronic diseases is propelling the growth of biologics safety testing. This trend is expected to drive the growth of the biologics safety testing market in the coming years.
Scope of the Report
Years Considered for the Study
2022-2029
Base Year
2023
Forecast Period
2024-2029
Units Considered
Value (USD) Billion
Segments
Product & Service, Test Type, Application, and End User
Regions covered
North America, Europe, Asia Pacific, Latin America, Middle East, and Africa
"The monoclonal antibodies development and manufacturing segment accounted for the largest share of by application segment in 2023."
In 2023, the monoclonal antibodies development and manufacturing segment accounted for the largest share of the global biologics safety testing market by application. Growing investments and funding in the development of novel biotherapeutics and rising demand for biological therapies for the treatment of chronic diseases are promoting the segment's growth in the biologics safety testing market.
"The US has continued to dominate the biologics safety testing market from 2024 to 2029."
The US dominated the biologics safety testing market in North America in 2023. The US is the world's largest biopharmaceutical market and a leader in biopharmaceutical research/investments. Also, US has strong healthcare infrastructure which drives the research and development in life sciences sector. Additionally, US has large number of biopharmaceutical companies; thus, increasing number of biopharmaceutical companies and growing research activities in biotechnology sector are propelling the market growth in US. Moreover, increasing approvals for biosimilars are also driving the growth of biologics safety testing market.
The primary interviews conducted for this report can be categorized as follows:
By Respondent: Supply Side- 60% and Demand Side 40%
By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
By Region: North America - 40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%
List of Companies Profiled in the Report:
Thermo Fisher Scientific Inc. (US)
Merck KGaA (Germany)
Lonza (Switzerland)
FUJIFILM Corporation (Japan)
Sartorius AG (Germany)
F. Hoffmann-La Roche Ltd (Switzerland)
Charles River Laboratories (US)
BIOMERIEUX (France)
Maravai LifeSciences (US)
WuXi AppTec (China)
SGS Societe Generale de Surveillance SA. (Switzerland)
Sotera Health (Nelson Laboratories, LLC) (US)
Samsung Biologics (South Korea)
GenScript (US)
Agilent Technologies, Inc. (US)
Syngene International Limited (India)
Eurofins Scientific (Luxembourg)
Laboratory Corporation of America Holdings (US)
Bio-Rad Laboratories, Inc. (US)
QIAGEN (Netherlands)
Promega Corporation (US)
Catalent, Inc (US)
ASSOCIATES OF CAPE COD, INC. (US)
Pacific BioLabs (US)
Clean Biologics (France)
PathoQuest (France)
ARL Bio Pharma, Inc. (US)
Frontage Labs (US)
Creative Biogene (US)
Advaxia Biologics (Italy)
Research Coverage:
This research report categorizes the biologics safety testing market by product & service (services (mycoplasma testing services, sterility testing services, endotoxin testing services, virus safety testing services, bioburden testing services, and other testing services), consumables, and instrument), test type (residual host-cell proteins & DNA detection tests, mycoplasma tests, sterility tests, endotoxin tests, virus safety tests, bioburden tests, other biologics safety tests), application (monoclonal antibodies development and manufacturing, vaccine development and manufacturing, cellular & gene therapy products development and manufacturing, blood & blood products development and manufacturing, other applications), end user (pharmaceutical & biotechnology companies, CROs and CDMOs, and academic & research institutes), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the biologics safety testing market. A thorough analysis of the key industry players has been done to provide insights into their business overview, products, services, solutions, key strategies, collaborations, partnerships, and agreements. Also, it includes new product launches, collaborations and acquisitions, and recent developments associated with the biologics safety testing market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall biologics safety testing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
Analysis of key drivers (growing development of mAbs and biosimilars, rising investments and fundings in biopharmaceutical industry, and stringent regulatory guidelines for biologics safety), restraints (ethical concern regarding animal testing), opportunities (growing opportunities in emerging economies, increasing focus on next generation therapeutics), and Challenges (high cost of biologics) influencing the growth of the market.
Product Development/Innovation: Detailed insights on newly launched products of the biologics safety testing market
Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the biologics safety testing market
Competitive Assessment: Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Lonza (Switzerland), FUJIFILM Corporation (Japan), Sartorius AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Charles River Laboratories (US), BIOMERIEUX (France), Maravai LifeSciences (US), WuXi AppTec (China), SGS Societe Generale de Surveillance SA. (Switzerland), Sotera Health (Nelson Laboratories, LLC) (US), Samsung Biologics (South Korea), GenScript (US), Agilent Technologies, Inc. (US), Syngene International Limited (India), Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), Bio-Rad Laboratories, Inc. (US), QIAGEN (Netherlands), Promega Corporation (US), Catalent, Inc (US), ASSOCIATES OF CAPE COD, INC. (US), Pacific BioLabs (US), Clean Biologics (France), PathoQuest (France), ARL Bio Pharma, Inc. (US), Frontage Labs (US), Creative Biogene (US), Advaxia Biologics (Italy), among others in the market.
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 REGIONS COVERED
1.4 YEARS CONSIDERED
1.5 CURRENCY CONSIDERED
1.6 STAKEHOLDERS
1.7 LIMITATIONS
1.8 SUMMARY OF CHANGES
1.9 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 BIOLOGICS SAFETY TESTING MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 GLOBAL MARKET SIZE ESTIMATION (BOTTOM-UP APPROACH)
8.2 MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING
8.2.1 GROWING REGULATORY APPROVALS FOR MONOCLONAL ANTIBODIES TO SUPPORT MARKET GROWTH
TABLE 142 BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY REGION, 2022-2029 (USD MILLION)
TABLE 143 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 144 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 145 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 146 LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 147 MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY REGION, 2022-2029 (USD MILLION)
TABLE 148 GCC: BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)
8.3 VACCINES DEVELOPMENT AND MANUFACTURING
8.3.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE GROWTH
TABLE 149 BIOLOGICS SAFETY TESTING MARKET FOR VACCINES DEVELOPMENT AND MANUFACTURING, BY REGION, 2022-2029 (USD MILLION)
TABLE 150 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR VACCINES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 151 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR VACCINES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 152 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR VACCINES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 153 LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR VACCINES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 154 MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET FOR VACCINES DEVELOPMENT AND MANUFACTURING, BY REGION, 2022-2029 (USD MILLION)
TABLE 155 GCC: BIOLOGICS SAFETY TESTING MARKET FOR VACCINES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)
8.4 CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING
8.4.1 INCREASING INVESTMENTS FOR DEVELOPMENT OF CELLULAR & GENE THERAPIES TO DRIVE GROWTH
TABLE 156 BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING, BY REGION, 2022-2029 (USD MILLION)
TABLE 157 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 158 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 159 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 160 LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 161 MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING, BY REGION, 2022-2029 (USD MILLION)
TABLE 162 GCC: BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)
8.5 BLOOD & BLOOD PRODUCTS DEVELOPMENT AND MANUFACTURING
8.5.1 GROWING DEMAND FOR BLOOD PRODUCTS TO PROPEL GROWTH
TABLE 163 BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD PRODUCTS DEVELOPMENT AND MANUFACTURING, BY REGION, 2022-2029 (USD MILLION)
TABLE 164 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 165 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 166 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 167 LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 168 MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD PRODUCTS DEVELOPMENT AND MANUFACTURING, BY REGION, 2022-2029 (USD MILLION)
TABLE 169 GCC: BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)
8.6 OTHER APPLICATIONS
TABLE 170 BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
TABLE 171 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 172 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 173 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 174 LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 175 MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
TABLE 176 GCC: BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
9 BIOLOGICS SAFETY TESTING MARKET, BY END USER
9.1 INTRODUCTION
TABLE 177 BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.2.1 INCREASING PHARMACEUTICAL R&D SPENDING AND GROWING STRATEGIC ALLIANCES TO DRIVE GROWTH
FIGURE 32 GLOBAL PHARMACEUTICAL R&D SPENDING, 2014-2028 (USD BILLION)
TABLE 178 BIOLOGICS SAFETY TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2029 (USD MILLION)
TABLE 179 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 180 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 181 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 182 LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 183 MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2029 (USD MILLION)
TABLE 184 GCC: BIOLOGICS SAFETY TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
9.3 CROS & CDMOS
9.3.1 INCREASING FOCUS ON EXPANSION OF CROS AND CDMOS TO PROPEL GROWTH
TABLE 185 BIOLOGICS SAFETY TESTING MARKET FOR CROS & CDMOS, BY REGION, 2022-2029 (USD MILLION)
TABLE 186 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR CROS & CDMOS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 187 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR CROS & CDMOS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 188 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR CROS & CDMOS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 189 LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR CROS & CDMOS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 190 MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET FOR CROS & CDMOS, BY REGION, 2022-2029 (USD MILLION)
TABLE 191 GCC: BIOLOGICS SAFETY TESTING MARKET FOR CROS & CDMOS, BY COUNTRY, 2022-2029 (USD MILLION)
9.4 ACADEMIC & RESEARCH INSTITUTES
9.4.1 SURGE IN R&D ACTIVITIES FOR DEVELOPMENT OF ADVANCED THERAPIES TO BOOST MARKET GROWTH
TABLE 192 BIOLOGICS SAFETY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022-2029 (USD MILLION)
TABLE 193 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 194 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 195 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 196 LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 197 MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022-2029 (USD MILLION)
TABLE 198 GCC: BIOLOGICS SAFETY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 428 ASSOCIATES OF CAPE COD, INC.: COMPANY OVERVIEW
12.3.4 CLEAN BIOLOGICS
TABLE 429 CLEAN BIOLOGICS: COMPANY OVERVIEW
12.3.5 PATHOQUEST
TABLE 430 PATHOQUEST: COMPANY OVERVIEW
12.3.6 PACIFIC BIOLABS
TABLE 431 PACIFIC BIOLABS: COMPANY OVERVIEW
12.3.7 ARL BIO PHARMA, INC.
TABLE 432 ARL BIO PHARMA, INC.: COMPANY OVERVIEW
12.3.8 FRONTAGE LABS
TABLE 433 FRONTAGE LABS: COMPANY OVERVIEW
12.3.9 CREATIVE BIOGENE
TABLE 434 CREATIVE BIOGENE: COMPANY OVERVIEW
12.3.10 ADVAXIA BIOLOGICS
TABLE 435 ADVAXIA BIOLOGICS: COMPANY OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
